Top

Journal of Experimental & Clinical Cancer Research

Published in:

Open Access 01-12-2017 | Review

Drug repurposing for the treatment of glioblastoma multiforme

Authors: Claudia Abbruzzese, Silvia Matteoni, Michele Signore, Luca Cardone, Kavindra Nath, Jerry D. Glickson, Marco G. Paggi

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2017

Abstract

Background

Glioblastoma Multiforme is the deadliest type of brain tumor and is characterized by very poor prognosis with a limited overall survival. Current optimal therapeutic approach has essentially remained unchanged for more than a decade, consisting in maximal surgical resection followed by radiotherapy plus temozolomide.

Main body

Such a dismal patient outcome represents a compelling need for innovative and effective therapeutic approaches. Given the development of new drugs is a process presently characterized by an immense increase in costs and development time, drug repositioning, finding new uses for existing approved drugs or drug repurposing, re-use of old drugs when novel molecular findings make them attractive again, are gaining significance in clinical pharmacology, since it allows faster and less expensive delivery of potentially useful drugs from the bench to the bedside. This is quite evident in glioblastoma, where a number of old drugs is now considered for clinical use, often in association with the first-line therapeutic intervention. Interestingly, most of these medications are, or have been, widely employed for decades in non-neoplastic pathologies without relevant side effects. Now, the refinement of their molecular mechanism(s) of action through up-to-date technologies is paving the way for their use in the therapeutic approach of glioblastoma as well as other cancer types.

Short conclusion

The spiraling costs of new antineoplastic drugs and the long time required for them to reach the market demands a profoundly different approach to keep lifesaving therapies affordable for cancer patients. In this context, repurposing can represent a relatively inexpensive, safe and fast approach to glioblastoma treatment. To this end, pros and cons must be accurately considered.

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96. doi: 10.1056/NEJMoa043330.PubMedCrossRef

Cloughesy TF, Cavenee WK, Mischel PS. Glioblastoma: from molecular pathology to targeted treatment. Annu Rev Pathol. 2014;9:1–25. doi: 10.1146/annurev-pathol-011110-130324. PubMedCrossRef

Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155(2):462–77. doi: 10.1016/j.cell.2013.09.034.PubMedPubMedCentralCrossRef

Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004;3(8):673–83. doi: 10.1038/nrd1468.PubMedCrossRef

Nosengo N. Can you teach old drugs new tricks? Nature. 2016;534(7607):314–6. doi: 10.1038/534314a.PubMedCrossRef

Zappacosta AR. Reversal of baldness in patient receiving minoxidil for hypertension. N Engl J Med. 1980;303(25):1480–1.PubMed

Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353(20):2148–57. doi: 10.1056/NEJMoa050010.PubMedCrossRef

Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil study group. N Engl J Med. 1998;338(20):1397–404. doi: 10.1056/NEJM199805143382001. PubMedCrossRef

Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341(21):1565–71. doi: 10.1056/NEJM199911183412102.PubMedCrossRef

10.

Furman PA, Fyfe JA, St Clair MH, Weinhold K, Rideout JL, Freeman GA, et al. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci U S A. 1986;83(21):8333–7.PubMedPubMedCentralCrossRef

11.

Foote MB, Papadopoulos N, Diaz LA Jr. Genetic classification of gliomas: refining histopathology. Cancer Cell. 2015;28(1):9–11. doi: 10.1016/j.ccell.2015.06.014.PubMedCrossRef

12.

Frattini V, Trifonov V, Chan JM, Castano A, Lia M, Abate F, et al. The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet. 2013;45(10):1141–9. doi: 10.1038/ng.2734.PubMedPubMedCentralCrossRef

13.

Ludwig K, Kornblum HI. Molecular markers in glioma. J Neuro-Oncol. 2017; doi: 10.1007/s11060-017-2379-y.

14.

Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, Campos C, et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science. 2013;340(6132):626–30. doi: 10.1126/science.1236062.PubMedPubMedCentralCrossRef

15.

Di Stefano AL, Fucci A, Frattini V, Labussiere M, Mokhtari K, Zoppoli P, et al. Detection, characterization, and inhibition of FGFR-TACC fusions in IDH wild-type glioma. Clin Cancer Res. 2015;21(14):3307–17. doi: 10.1158/1078-0432.CCR-14-2199.PubMedPubMedCentralCrossRef

16.

Zhang Y, Kwok-Shing Ng P, Kucherlapati M, Chen F, Liu Y, Tsang YH, et al. A pan-cancer Proteogenomic atlas of PI3K/AKT/mTOR pathway alterations. Cancer Cell. 2017;31(6):820–832 e3. doi: 10.1016/j.ccell.2017.04.013.PubMedCrossRef

17.

Lerner RG, Grossauer S, Kadkhodaei B, Meyers I, Sidorov M, Koeck K, et al. Targeting a Plk1-controlled polarity checkpoint in therapy-resistant glioblastoma-propagating cells. Cancer Res. 2015;75(24):5355–66. doi: 10.1158/0008-5472.CAN-14-3689.PubMedPubMedCentralCrossRef

18.

Singh D, Chan JM, Zoppoli P, Niola F, Sullivan R, Castano A, et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science. 2012;337(6099):1231–5. doi: 10.1126/science.1220834.PubMedPubMedCentralCrossRef

19.

Furnari FB, Cloughesy TF, Cavenee WK, Mischel PS. Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma. Nat Rev Cancer. 2015;15(5):302–10. doi: 10.1038/nrc3918.PubMedPubMedCentralCrossRef

20.

Meyer M, Reimand J, Lan X, Head R, Zhu X, Kushida M, et al. Single cell-derived clonal analysis of human glioblastoma links functional and genomic heterogeneity. Proc Natl Acad Sci U S A. 2015;112(3):851–6. doi: 10.1073/pnas.1320611111.PubMedPubMedCentralCrossRef

21.

Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366(10):883–92. doi: 10.1056/NEJMoa1113205.PubMedPubMedCentralCrossRef

22.

Prasad V. Perspective: the precision-oncology illusion. Nature. 2016;537(7619):S63. doi: 10.1038/537S63a.PubMedCrossRef

23.

Liu Z, Fang H, Reagan K, Xu X, Mendrick DL, Slikker W Jr, et al. In silico drug repositioning: what we need to know. Drug Discov Today. 2013;18(3–4):110–5. doi: 10.1016/j.drudis.2012.08.005.PubMedCrossRef

24.

Patel MN, Halling-Brown MD, Tym JE, Workman P, Al-Lazikani B. Objective assessment of cancer genes for drug discovery. Nat Rev Drug Discov. 2013;12(1):35–50. doi: 10.1038/nrd3913. PubMedCrossRef

25.

Berger SI, Iyengar R. Network analyses in systems pharmacology. Bioinformatics. 2009;25(19):2466–72. doi: 10.1093/bioinformatics/btp465.PubMedPubMedCentralCrossRef

26.

Iorio F, Rittman T, Ge H, Menden M, Saez-Rodriguez J. Transcriptional data: a new gateway to drug repositioning? Drug Discov Today. 2013;18(7–8):350–7. doi: 10.1016/j.drudis.2012.07.014.PubMedPubMedCentralCrossRef

27.

Cardone L. Biocomputing drug repurposing toward targeted therapies. Aging (Albany NY). 2016;8(11):2609–10. 10.18632/aging.101135.CrossRef

28.

Parkinson H, Sarkans U, Kolesnikov N, Abeygunawardena N, Burdett T, Dylag M, et al. ArrayExpress update--an archive of microarray and high-throughput sequencing-based functional genomics experiments. Nucleic Acids Res. 2011;39(Database):D1002–4. doi: 10.1093/nar/gkq1040.PubMedCrossRef

29.

Barrett T, Suzek TO, Troup DB, Wilhite SE, Ngau WC, Ledoux P, et al. NCBI GEO: mining millions of expression profiles--database and tools. Nucleic Acids Res. 2005;33(Database issue):D562–6. doi: 10.1093/nar/gki022.PubMedCrossRef

30.

Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, et al. The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006;313(5795):1929–35. doi: 10.1126/science.1132939.PubMedCrossRef

31.

Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protocols. 2008;4(1):44–57. doi: 10.1038/nprot.2008.211.CrossRef

32.

Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–50. doi: 10.1073/pnas.0506580102.PubMedPubMedCentralCrossRef

33.

Culhane AC, Schwarzl T, Sultana R, Picard KC, Picard SC, Lu TH, et al. GeneSigDB--a curated database of gene expression signatures. Nucleic Acids Res. 2010;38(Database issue):D716–25. doi: 10.1093/nar/gkp1015.PubMedCrossRef

34.

Iorio F, Bosotti R, Scacheri E, Belcastro V, Mithbaokar P, Ferriero R, et al. Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc Natl Acad Sci U S A. 2010;107(33):14621–6. doi: 10.1073/pnas.1000138107.PubMedPubMedCentralCrossRef

35.

Carrella D, Manni I, Tumaini B, Dattilo R, Papaccio F, Mutarelli M, et al. Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDA-approved compounds. Oncotarget. 2016;7(37):58743–58. 10.18632/oncotarget.11318.PubMedPubMedCentralCrossRef

36.

Ghosh JC, Siegelin MD, Vaira V, Faversani A, Tavecchio M, Chae YC, et al. Adaptive mitochondrial reprogramming and resistance to PI3K therapy. J Natl Cancer Inst. 2015;107(3) doi: 10.1093/jnci/dju502.

37.

Nevins JR, Potti A. Mining gene expression profiles: expression signatures as cancer phenotypes. Nat Rev Genet. 2007;8(8):601–9. doi: 10.1038/nrg2137.PubMedCrossRef

38.

Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature. 2006;439(7074):353–7. doi: 10.1038/nature04296.PubMedCrossRef

39.

Zhang Y, Cruickshanks N, Yuan F, Wang B, Pahuski M, Wulfkuhle J, et al. Targetable T-type calcium channels drive glioblastoma. Cancer Res. 2017;77(13):3479–90. doi: 10.1158/0008-5472.CAN-16-2347.PubMedCrossRef

40.

Gerber DE, Minna JD. ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time. Cancer Cell. 2010;18(6):548–51. doi: 10.1016/j.ccr.2010.11.033.PubMedPubMedCentralCrossRef

41.

Jones LH, Neubert H. Clinical chemoproteomics-opportunities and obstacles. Sci Transl Med. 2017;9(386) doi: 10.1126/scitranslmed.aaf7951.

42.

Cheng F, Hong H, Yang S, Wei Y. Individualized network-based drug repositioning infrastructure for precision oncology in the panomics era. Brief Bioinform. 2017;18(4):682–97. doi: 10.1093/bib/bbw051. PubMed

43.

McCarthy JJ, McLeod HL, Ginsburg GS. Genomic medicine: a decade of successes, challenges, and opportunities. Sci Transl Med. 2013;5(189):189sr4. doi: 10.1126/scitranslmed.3005785.PubMedCrossRef

44.

Molenaar RJ, Coelen RJ, Khurshed M, Roos E, Caan MW, van Linde ME, et al. Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with IDH1-mutated or IDH2-mutated solid tumours. BMJ Open. 2017;7(6):e014961. doi: 10.1136/bmjopen-2016-014961.PubMedPubMedCentralCrossRef

45.

Chen X, Wong YK, Wang J, Zhang J, Lee YM, Shen HM, et al. Target identification with quantitative activity based protein profiling (ABPP). Proteomics. 2017;17(3–4) doi: 10.1002/pmic.201600212.

46.

Barglow KT, Cravatt BF. Activity-based protein profiling for the functional annotation of enzymes. Nat Methods. 2007;4(10):822–7. doi: 10.1038/nmeth1092.PubMedCrossRef

47.

Pierobon M, Wulfkuhle J, Liotta L, Petricoin E. Application of molecular technologies for phosphoproteomic analysis of clinical samples. Oncogene. 2015;34(7):805–14. doi: 10.1038/onc.2014.16.PubMedCrossRef

48.

Pierobon M, VanMeter AJ, Moroni N, Galdi F, Petricoin EF III. Reverse-phase protein microarrays. Methods MolBiol. 2012;823:215–35. doi: 10.1007/978–1–60327-216-2_14.

49.

Shestov AA, Lee SC, Nath K, Guo L, Nelson DS, Roman JC, et al. (13)C MRS and LC-MS flux analysis of tumor intermediary metabolism. Front Oncol. 2016;6:135. doi: 10.3389/fonc.2016.00135.PubMedPubMedCentralCrossRef

50.

Rasper M, Schafer A, Piontek G, Teufel J, Brockhoff G, Ringel F, et al. Aldehyde dehydrogenase 1 positive glioblastoma cells show brain tumor stem cell capacity. Neuro-Oncology. 2010;12(10):1024–33. doi: 10.1093/neuonc/noq070.PubMedPubMedCentralCrossRef

51.

Schafer A, Teufel J, Ringel F, Bettstetter M, Hoepner I, Rasper M, et al. Aldehyde dehydrogenase 1A1--a new mediator of resistance to temozolomide in glioblastoma. Neuro-Oncology. 2012;14(12):1452–64. doi: 10.1093/neuonc/nos270.PubMedPubMedCentralCrossRef

52.

Mashimo T, Pichumani K, Vemireddy V, Hatanpaa KJ, Singh DK, Sirasanagandla S, et al. Acetate is a bioenergetic substrate for human glioblastoma and brain metastases. Cell. 2014;159(7):1603–14. doi: 10.1016/j.cell.2014.11.025.PubMedPubMedCentralCrossRef

53.

Triscott J, Rose Pambid M, Dunn SE. Concise review: bullseye: targeting cancer stem cells to improve the treatment of gliomas by repurposing disulfiram. Stem Cells. 2015;33(4):1042–6. doi: 10.1002/stem.1956. PubMedCrossRef

54.

Lun X, Wells JC, Grinshtein N, King JC, Hao X, Dang NH, et al. Disulfiram when combined with copper enhances the therapeutic effects of temozolomide for the treatment of glioblastoma. Clin Cancer Res. 2016; doi: 10.1158/1078-0432.CCR-15-1798.

55.

Liu P, Brown S, Goktug T, Channathodiyil P, Kannappan V, Hugnot JP, et al. Cytotoxic effect of disulfiram/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells. Br J Cancer. 2012;107(9):1488–97. doi: 10.1038/bjc.2012.442.PubMedPubMedCentralCrossRef

56.

Triscott J, Lee C, Hu K, Fotovati A, Berns R, Pambid M, et al. Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma and over-rides resistance to temozolomide. Oncotarget. 2012;3(10):1112–23. 10.18632/oncotarget.604.PubMedPubMedCentralCrossRef

57.

Paranjpe A, Zhang R, Ali-Osman F, Bobustuc GC, Srivenugopal KS. Disulfiram is a direct and potent inhibitor of human O6-methylguanine-DNA methyltransferase (MGMT) in brain tumor cells and mouse brain and markedly increases the alkylating DNA damage. Carcinogenesis. 2014;35(3):692–702. doi: 10.1093/carcin/bgt366.PubMedCrossRef

58.

Seto B. Rapamycin and mTOR: a serendipitous discovery and implications for breast cancer. Clin Transl Med. 2012;1(1):29. https://doi.org/10.1186/2001-1326-1-29.PubMedPubMedCentralCrossRef

59.

Hegazy AM, Yamada D, Kobayashi M, Kohno S, Ueno M, Ali MA, et al. Therapeutic strategy for targeting aggressive malignant gliomas by disrupting their energy balance. J Biol Chem. 2016; doi: 10.1074/jbc.M116.734756.

60.

Bride KL, Vincent T, Smith-Whitley K, Lambert MP, Bleesing JJ, Seif AE, et al. Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. Blood. 2016;127(1):17–28. doi: 10.1182/blood-2015-07-657981.PubMedPubMedCentralCrossRef

61.

Johnson SC, Rabinovitch PS, Kaeberlein M. mTOR is a key modulator of ageing and age-related disease. Nature. 2013;493(7432):338–45. doi: 10.1038/nature11861.PubMedPubMedCentralCrossRef

62.

Lamming DW, Ye L, Sabatini DM, Baur JA. Rapalogs and mTOR inhibitors as anti-aging therapeutics. J Clin Invest. 2013;123(3):980–9. doi: 10.1172/JCI64099.PubMedPubMedCentralCrossRef

63.

Wick W, Gorlia T, Bady P, Platten M, van den Bent MJ, Taphoorn MJ, et al. Phase II study of radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter Hypermethylation (EORTC 26082). Clin Cancer Res. 2016;22(19):4797–806. doi: 10.1158/1078-0432.CCR-15-3153.PubMedCrossRef

64.

Wu L, Zhou B, Oshiro-Rapley N, Li M, Paulo JA, Webster CM, et al. An ancient, unified mechanism for metformin growth inhibition in C. Elegans and cancer. Cell. 2016;167(7):1705–1718 e13. doi: 10.1016/j.cell.2016.11.055.PubMedCrossRef

65.

Pollak MN. Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov. 2012;2(9):778–90. doi: 10.1158/2159-8290.CD-12-0263.PubMedCrossRef

66.

Morales DR, Morris AD. Metformin in cancer treatment and prevention. Annu Rev Med. 2015;66:17–29. doi: 10.1146/annurev-med-062613-093128.PubMedCrossRef

67.

Howell JJ, Hellberg K, Turner M, Talbott G, Kolar MJ, Ross DS, et al. Metformin inhibits hepatic mTORC1 signaling via dose-dependent mechanisms involving AMPK and the TSC complex. Cell Metab. 2017;25(2):463–71. doi: 10.1016/j.cmet.2016.12.009.PubMedCrossRef

68.

Pernicova I, Korbonits M. Metformin-mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol. 2014;10(3):143–56. doi: 10.1038/nrendo.2013.256.PubMedCrossRef

69.

Hart T, Dider S, Han W, Xu H, Zhao Z, Xie L. Toward repurposing metformin as a precision anti-cancer therapy using structural systems pharmacology. Sci Rep. 2016;6:20441. doi: 10.1038/srep20441.PubMedPubMedCentralCrossRef

70.

Strong R, Miller RA, Antebi A, Astle CM, Bogue M, Denzel MS, et al. Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an alpha-glucosidase inhibitor or a Nrf2-inducer. Aging Cell. 2016; doi: 10.1111/acel.12496.

71.

Coyle C, Cafferty FH, Vale C, Langley RE. Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis. Ann Oncol. 2016;27(12):2184–95. doi: 10.1093/annonc/mdw410.PubMedPubMedCentralCrossRef

72.

Coulston F, Dougherty WJ, LeFevre R, Abraham R, Silvestrini B. Reversible inhibition of spermatogenesis in rats and monkeys with a new class of indazol-carboxylic acids. Exp Mol Pathol. 1975;23(2):357–66.PubMedCrossRef

73.

Nath K, Guo L, Nancolas B, Nelson DS, Shestov AA, Lee SC, et al. Mechanism of antineoplastic activity of lonidamine. Biochim Biophys Acta. 2016;1866(2):151–62. doi: 10.1016/j.bbcan.2016.08.001.PubMed

74.

Magno L, Terraneo F, Bertoni F, Tordiglione M, Bardelli D, Rosignoli MT, et al. Double-blind randomized study of lonidamine and radiotherapy in head and neck cancer. Int J Radiat Oncol Biol Phys. 1994;29(1):45–55.PubMedCrossRef

75.

Carapella CM, Paggi MG, Calvosa F, Cattani F, Jandolo B, Mastrostefano R, et al. Lonidamine in the combined treatment of malignant gliomas. A randomized study. J Neurosurg Sci. 1990;34(3–4):261–4.PubMed

76.

Schiffer D, Sales S, Soffietti R. Lonidamine in malignant brain tumors. Semin Oncol. 1991;18(2 Suppl 4):38–41.PubMed

77.

Guo L, Shestov AA, Worth AJ, Nath K, Nelson DS, Leeper DB, et al. Inhibition of mitochondrial complex II by the anticancer agent Lonidamine. J Biol Chem. 2016;291(1):42–57. doi: 10.1074/jbc.M115.697516.PubMedCrossRef

78.

Nancolas B, Guo L, Zhou R, Nath K, Nelson DS, Leeper DB, et al. The anti-tumour agent lonidamine is a potent inhibitor of the mitochondrial pyruvate carrier and plasma membrane monocarboxylate transporters. Biochem J. 2016;473(7):929–36. doi: 10.1042/BJ20151120.PubMedPubMedCentralCrossRef

79.

Paggi MG, Zupi G, Fanciulli M, Del Carlo C, Giorno S, Laudonio N, et al. Effect of lonidamine on the utilization of ¹⁴C-labeled glucose by human astrocytoma cells. Exp Mol Pathol. 1987;47(2):154–65.PubMedCrossRef

80.

Floridi A, Lehninger AL. Action of the antitumor and antispermatogenic agent lonidamine on electron transport in Ehrlich ascites tumor mitochondria. Arch Biochem Biophys. 1983;226(1):73–83.PubMedCrossRef

81.

Davidescu M, Macchioni L, Scaramozzino G, Cristina Marchetti M, Migliorati G, Vitale R, et al. The energy blockers bromopyruvate and lonidamine lead GL15 glioblastoma cells to death by different p53-dependent routes. Sci Rep. 2015;5:14343. doi: 10.1038/srep14343.PubMedPubMedCentralCrossRef

82.

Nath K, Nelson DS, Heitjan DF, Leeper DB, Zhou R, Glickson JD. Lonidamine induces intracellular tumor acidification and ATP depletion in breast, prostate and ovarian cancer xenografts and potentiates response to doxorubicin. NMR Biomed. 2015;28(3):281–90. doi: 10.1002/nbm.3240.PubMedCrossRef

83.

Schmeisser S, Zarse K, Ristow M. Lonidamine extends lifespan of adult Caenorhabditis Elegans by increasing the formation of mitochondrial reactive oxygen species. Horm Metab Res. 2011;43(10):687–92. doi: 10.1055/s-0031-1286308.PubMedCrossRef

84.

Tommasino C, Gambardella L, Buoncervello M, Griffin RJ, Golding BT, Alberton M, et al. New derivatives of the antimalarial drug Pyrimethamine in the control of melanoma tumor growth: an in vitro and in vivo study. J Exp Clin Cancer Res. 2016;35(1):137. doi: 10.1186/s13046-016-0409-9. PubMedPubMedCentralCrossRef

85.

Levy JMM, Towers CG, Thorburn A. Targeting autophagy in cancer. Nat Rev Cancer. 2017;17(9):528–42. doi: 10.1038/nrc.2017.53.PubMedCrossRef

86.

Wang Z, Liu P, Chen Q, Deng S, Liu X, Situ H, et al. Targeting AMPK signaling pathway to overcome drug resistance for cancer therapy. Curr Drug Targets. 2016;17(8):853–64.PubMedCrossRef

87.

Yoshida GJ. Metabolic reprogramming: the emerging concept and associated therapeutic strategies. J Exp Clin Cancer Res. 2015;34(1):111. doi: 10.1186/s13046-015-0221-y. PubMedPubMedCentralCrossRef

88.

Vitale I, Manic G, Dandrea V, De Maria R. Role of autophagy in the maintenance and function of cancer stem cells. Int J Dev Biol. 2015;59(1–3):95–108. doi: 10.1387/ijdb.150082iv.PubMedCrossRef

89.

Yan Y, Xu Z, Dai S, Qian L, Sun L, Gong Z. Targeting autophagy to sensitive glioma to temozolomide treatment. J Exp Clin Cancer Res. 2016;35:23. doi: 10.1186/s13046-016-0303-5.PubMedPubMedCentralCrossRef

90.

Li C, Liu Y, Liu H, Zhang W, Shen C, Cho K, et al. Impact of autophagy inhibition at different stages on cytotoxic effect of autophagy inducer in glioblastoma cells. Cell Physiol Biochem. 2015;35(4):1303–16. doi: 10.1159/000373952.PubMedCrossRef

91.

Choi DS, Blanco E, Kim YS, Rodriguez AA, Zhao H, Huang TH, et al. Chloroquine eliminates cancer stem cells through deregulation of Jak2 and DNMT1. Stem Cells. 2014;32(9):2309–23. doi: 10.1002/stem.1746. PubMedPubMedCentralCrossRef

92.

Kimura T, Takabatake Y, Takahashi A, Isaka Y. Chloroquine in cancer therapy: a double-edged sword of autophagy. Cancer Res. 2013;73(1):3–7. doi: 10.1158/0008-5472.CAN-12-2464.PubMedCrossRef

93.

Pascolo S. Time to use a dose of chloroquine as an adjuvant to anti-cancer chemotherapies. Eur J Pharmacol. 2016;771:139–44. doi: 10.1016/j.ejphar.2015.12.017.PubMedCrossRef

94.

Lee SW, Kim HK, Lee NH, Yi HY, Kim HS, Hong SH, et al. The synergistic effect of combination temozolomide and chloroquine treatment is dependent on autophagy formation and p53 status in glioma cells. Cancer Lett. 2015;360(2):195–204. doi: 10.1016/j.canlet.2015.02.012.PubMedCrossRef

95.

Hori YS, Hosoda R, Akiyama Y, Sebori R, Wanibuchi M, Mikami T, et al. Chloroquine potentiates temozolomide cytotoxicity by inhibiting mitochondrial autophagy in glioma cells. J Neuro-Oncol. 2015;122(1):11–20. doi: 10.1007/s11060-014-1686-9.CrossRef

96.

Rosenfeld MR, Ye X, Supko JG, Desideri S, Grossman SA, Brem S, et al. A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme. Autophagy. 2014;10(8):1359–68. doi: 10.4161/auto.28984.PubMedPubMedCentralCrossRef

97.

Briceno E, Reyes S, Sotelo J. Therapy of glioblastoma multiforme improved by the antimutagenic chloroquine. Neurosurg Focus. 2003;14(2):e3.PubMedCrossRef

98.

Sotelo J, Briceno E, Lopez-Gonzalez MA. Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2006;144(5):337–43.PubMedCrossRef

99.

Briceno E, Calderon A, Sotelo J. Institutional experience with chloroquine as an adjuvant to the therapy for glioblastoma multiforme. Surg Neurol. 2007;67(4):388–91. doi: 10.1016/j.surneu.2006.08.080.PubMedCrossRef

100.

Golden EB, Cho HY, Hofman FM, Louie SG, Schonthal AH, Chen TC. Quinoline-based antimalarial drugs: a novel class of autophagy inhibitors. Neurosurg Focus. 2015;38(3):E12. https://doi.org/10.3171/2014.12.FOCUS14748.PubMedCrossRef

101.

Lee MS, Johansen L, Zhang Y, Wilson A, Keegan M, Avery W, et al. The novel combination of chlorpromazine and pentamidine exerts synergistic antiproliferative effects through dual mitotic action. Cancer Res. 2007;67(23):11359–67. doi: 10.1158/0008-5472.CAN-07-2235.PubMedCrossRef

102.

Shin SY, Lee KS, Choi YK, Lim HJ, Lee HG, Lim Y, et al. The antipsychotic agent chlorpromazine induces autophagic cell death by inhibiting the Akt/mTOR pathway in human U-87MG glioma cells. Carcinogenesis. 2013;34(9):2080–9. https://doi.org/10.1093/carcin/bgt169.PubMedCrossRef

103.

Dolma S, Selvadurai HJ, Lan X, Lee L, Kushida M, Voisin V, et al. Inhibition of dopamine receptor D4 impedes Autophagic flux, proliferation, and survival of glioblastoma stem cells. Cancer Cell. 2016;29(6):859–73. doi: 10.1016/j.ccell.2016.05.002.PubMedCrossRef

104.

Fan Q, Aksoy O, Wong RA, Ilkhanizadeh S, Novotny CJ, Gustafson WC, et al. A kinase inhibitor targeted to mTORC1 drives regression in glioblastoma. Cancer Cell. 2017;31(3):424–35. doi: 10.1016/j.ccell.2017.01.014.PubMedCrossRef

105.

Tanaka K, Sasayama T, Irino Y, Takata K, Nagashima H, Satoh N, et al. Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment. J Clin Invest. 2015;125(4):1591–602. doi: 10.1172/JCI78239.PubMedPubMedCentralCrossRef

106.

Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell. 2012;21(3):297–308. doi: 10.1016/j.ccr.2012.02.014.PubMedPubMedCentralCrossRef

107.

Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. NatRevCancer. 2011;11(2):85–95. doi:nrc2981 [pii];doi: 10.1038/nrc2981 [doi].

108.

Pedersen PL. Warburg, me and hexokinase 2: multiple discoveries of key molecular events underlying one of cancers' most common phenotypes, the "Warburg effect", i.E., elevated glycolysis in the presence of oxygen. J Bioenerg Biomembr. 2007;39(3):211–22. doi: 10.1007/s10863-007-9094-x.PubMedCrossRef

109.

Floridi A, Paggi MG, Fanciulli M. Modulation of glycolysis in neuroepithelial tumors. J Neurosurg Sci. 1989;33(1):55–64.PubMed

110.

Paggi MG, Fanciulli M, Del Carlo C, Citro G, Carapella CM, Floridi A. The membrane-bound hexokinase as a potential marker for malignancy in human gliomas. J Neurosurg Sci. 1990;34:209–13.PubMed

111.

Zhou Y, Zhou Y, Shingu T, Feng L, Chen Z, Ogasawara M, et al. Metabolic alterations in highly tumorigenic glioblastoma cells: preference for hypoxia and high dependency on glycolysis. J Biol Chem. 2011;286(37):32843–53. doi: 10.1074/jbc.M111.260935.PubMedPubMedCentralCrossRef

112.

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74. doi: 10.1016/j.cell.2011.02.013.PubMedCrossRef

113.

Roberts DJ, Tan-Sah VP, Ding EY, Smith JM, Miyamoto S. Hexokinase-II positively regulates glucose starvation-induced autophagy through TORC1 inhibition. Mol Cell. 2014;53(4):521–33. doi: 10.1016/j.molcel.2013.12.019.PubMedPubMedCentralCrossRef

114.

Sanduja S, Feng Y, Mathis RA, Sokol ES, Reinhardt F, Halaban R, et al. AMPK promotes tolerance to Ras pathway inhibition by activating autophagy. Oncogene. 2016;35(40):5295–303. doi: 10.1038/onc.2016.70.PubMedCrossRef

115.

YL H, DeLay M, Jahangiri A, Molinaro AM, Rose SD, Carbonell WS, et al. Hypoxia-induced autophagy promotes tumor cell survival and adaptation to antiangiogenic treatment in glioblastoma. Cancer Res. 2012;72(7):1773–83. doi: 10.1158/0008-5472.CAN-11-3831.CrossRef

116.

Talarico C, Dattilo V, D'Antona L, Menniti M, Bianco C, Ortuso F, et al. SGK1, the new player in the game of resistance: chemo-radio molecular target and strategy for inhibition. Cell Physiol Biochem. 2016;39(5):1863–76. doi: 10.1159/000447885.PubMedCrossRef

117.

D'Antona L, Amato R, Talarico C, Ortuso F, Menniti M, Dattilo V, et al. SI113, a specific inhibitor of the Sgk1 kinase activity that counteracts cancer cell proliferation. Cell Physiol Biochem. 2015;35(5):2006–18. doi: 10.1159/000374008.PubMedCrossRef

Title: Drug repurposing for the treatment of glioblastoma multiforme
Authors: Claudia Abbruzzese
Silvia Matteoni
Michele Signore
Luca Cardone
Kavindra Nath
Jerry D. Glickson
Marco G. Paggi
Publication date: 01-12-2017
Publisher: BioMed Central
Published in: Journal of Experimental & Clinical Cancer Research / Issue 1/2017
Electronic ISSN: 1756-9966
DOI: https://doi.org/10.1186/s13046-017-0642-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Main body

Short conclusion

Please log in to get access to this content

Other articles of this Issue 1/2017

Synthetic regulatory RNAs selectively suppress the progression of bladder cancer

hrHPV E5 oncoprotein: immune evasion and related immunotherapies

High expression of Collagen Triple Helix Repeat Containing 1 (CTHRC1) facilitates progression of oesophageal squamous cell carcinoma through MAPK/MEK/ERK/FRA-1 activation

PDL1 And LDHA act as ceRNAs in triple negative breast cancer by regulating miR-34a

Dihydroartemisinin inhibits TCTP-dependent metastasis in gallbladder cancer

Downregulation of MiR-31 stimulates expression of LATS2 via the hippo pathway and promotes epithelial-mesenchymal transition in esophageal squamous cell carcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer